id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9287 R32243 |
Aydin (Valproate) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.09 [0.00;2.17] C excluded (control group) |
0/11 2/7 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9288 R32253 |
Aydin (Valproate) (Controls unexposed, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.37 [0.02;8.48] C | 0/11 2/22 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9324 R32504 |
Putignano (Valproate), 2019 | Intensive care unit (ICU) stay | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.40 [0.07;29.36] C | 0/131 2/917 | 2 | 131 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9314 R32449 |
Bank (Valproate) (Mixed indications), 2017 | Admission to neonatal intensive care unit (NICU) or Special Care Nursery | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.41 [0.02;8.43] C | 0/6 6/36 | 6 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9283 R32203 |
Artama (Valproate) (Controls exposed to Lamotrigine, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.22 [0.75;1.97] C excluded (control group) |
110/600 24/154 | 134 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9284 R32215 |
Artama (Valproate) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
2.59 [2.09;3.21] excluded (control group) |
110/600 49,612/689,482 | 49,722 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9285 R32227 |
Artama (Valproate) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 2.02 [1.53;2.67] | 110/600 152/1,708 | 262 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9328 R32527 |
Viinikainen (Valproate) (Controls unexposed, disease free) a, 2006 | Admission to a neonatal unit | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 2.10 [0.73;6.06] C | 4/28 1,822/24,778 | 1,826 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9297 R32322 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [1.00;15058.31] C excluded (control group) |
0/1 0/62 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9298 R32351 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.12;1923.88] C | 0/1 0/8 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 1.98 [1.52;2.59] | 2,098 | 777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick; 2: Valproate; 3: Valproate) (Mixed indications; 4: Valproate) (Controls unexposed, sick; 5: Valproate) (Controls unexposed, disease free) ; 6: Valproate) (Controls unexposed, sick;
Asymetry test p-value = 0.4592 (by Egger's regression)
slope=0.7533 (0.1360); intercept=-0.3350 (0.4095); t=0.8181; p=0.4592
excluded 9297, 9283, 9284, 9287